{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-25-000027","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.306387+00:00","generated_at":"2026-05-17T00:13:32.929944+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aquestive Q3 net loss $15.4M; Anaphylm PDUFA Jan 31, 2026, launch prep ongoing","bullets":["Total revenue $12.8M (+4% YoY excluding one-time 2024 deferred revenue); net loss $15.4M ($0.14/sh) vs $11.5M loss in Q3 2024.","Cash $129.1M; full-year 2025 revenue guidance $44-50M, non-GAAP adjusted EBITDA loss $47-51M.","Anaphylm NDA on track for Jan 31, 2026 PDUFA; FDA will not hold AdCom; US launch planned Q1 2026 if approved.","Two new Anaphylm patents issued Oct 2025 extending protection to 2037; IND for AQST-108 topical epinephrine gel for alopecia areata on track for Q4 2025.","Added clinical leadership for AdrenaVerse pipeline; supply chain largely unaffected by tariffs."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-25-000027","json":"https://secwatch.observer/filing/0001398733-25-000027.json","markdown":"https://secwatch.observer/filing/0001398733-25-000027.md","text":"https://secwatch.observer/filing/0001398733-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/0001398733-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/aqst-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:13:32.929944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}